Neoadjuvant vs Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small Cell Lung Cancer

CONCLUSIONS: Neoadjuvant chemoimmunotherapy confers a significant OS benefit over adjuvant chemoimmunotherapy for patients with resectable stage II-IIIB NSCLC. Although randomized trials are needed to confirm our findings, strong consideration should be given to administering neoadjuvant chemoimmunotherapy to patients who are predetermined to receive systemic treatment.PMID:38290596 | DOI:10.1016/j.athoracsur.2024.01.004

Source: The Annals of Thoracic Surgery - January 30, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Russell Seth Martins Syed Shahzad Razi Ahmed Alnajar Kostantinos Poulikidis M Jawad Latif Jeffrey Luo Faiz Y Bhora Source Type: research